Vantis Vascular develops the CrossFAST™ Integrated Microcatheter Advanced Delivery System, a dual monorail microcatheter delivery platform for complex coronary and peripheral interventions. The system uses DuoPRO™ Interlocking Technology to couple the microcatheter to the outer delivery catheter, enabling the unit to be advanced as one device for improved pushability and navigation. Vantis positions the CrossFAST System to reduce adverse events during catheter delivery and address limitations of guide extension catheters in high-risk procedures. The CrossFAST System is commercially available in the U.S. as part of a limited market release, with a full market release planned in 2025. The company is led by CEO Jason Turner and is focused on U.S. commercialization efforts. The company has previously raised $30M to date from high-net-worth individuals and National Institutes of Health grants and plans to use new funding to support commercial launch. Vantis Vascular develops performance-driven vascular intervention technologies, including the CrossFAST Integrated Microcatheter Guide Extension System and the CrossSHOCK Intravascular Lithotripsy (IVL) System. Both products are described as next-generation solutions intended to improve delivery, safety, and efficacy in treating calcified and tortuous arteries. The company says products are currently in development and are not commercially available for sale. Vantis aims to accelerate development and support a near-term commercial launch of the CrossFAST system. The company has raised capital to date from high-net-worth individuals and NIH grants and is using new financing to advance its development and commercialization plans.

Total raised

$15M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2024